ALXO
Income statement / Annual
Last year (2023), ALX Oncology Holdings Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, ALX Oncology Holdings Inc.'s net income was -$160.81 M.
See ALX Oncology Holdings Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$1.18 M
|
$4.80 M
|
$2.07 M
|
| Cost of Revenue |
$836,000.00 |
$1.47 M |
$736,000.00 |
$1.08 M |
$4.36 M |
$1.88 M |
| Gross Profit |
-$836,000.00 |
-$1.47 M |
-$736,000.00 |
$107,000.00 |
$436,000.00 |
$187,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0.09 |
0.09 |
0.09 |
| Research and Development
Expenses |
$141.80 M
|
$98.40 M
|
$60.17 M
|
$28.96 M
|
$16.31 M
|
$11.27 M
|
| General & Administrative
Expenses |
$28.48 M
|
$29.04 M
|
$23.39 M
|
$14.81 M
|
$3.31 M
|
$2.60 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$28.48 M
|
$29.04 M
|
$23.39 M
|
$14.81 M
|
$3.31 M
|
$2.60 M
|
| Other Expenses |
$0.00 |
-$260,000.00 |
$84,000.00 |
-$404,000.00 |
-$5,000.00 |
-$2,000.00 |
| Operating Expenses |
$170.28 M |
$127.44 M |
$83.56 M |
$43.77 M |
$19.62 M |
$13.87 M |
| Cost And Expenses |
$170.28 M |
$127.44 M |
$83.56 M |
$44.85 M |
$23.98 M |
$15.75 M |
| Interest Income |
$10.65 M |
$4.04 M |
$91.00 |
$124,000.00 |
$21.00 |
$0.00 |
| Interest Expense |
$1.57 M |
$0.00 |
$13,000.00 |
$811,000.00 |
$21,000.00 |
$0.00 |
| Depreciation &
Amortization |
$836,000.00
|
$1.47 M
|
$736,000.00
|
$202,000.00
|
$429,000.00
|
$431,000.00
|
| EBITDA |
-$158.40 M
|
-$121.95 M
|
-$83.47 M
|
-$43.46 M
|
-$18.76 M
|
-$13.26 M
|
| EBITDA Ratio |
0 |
0 |
0 |
-37.28 |
-3.91 |
-6.41 |
| Operating Income Ratio
|
0
|
0
|
0
|
-36.94
|
-4
|
-6.62
|
| Total Other
Income/Expenses Net |
$9.47 M
|
$4.02 M
|
$71,000.00
|
-$1.84 M
|
-$26,000.00
|
-$2,000.00
|
| Income Before Tax |
-$160.81 M |
-$123.42 M |
-$83.48 M |
-$45.50 M |
-$19.21 M |
-$13.69 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
-38.49
|
-4.01
|
-6.62
|
| Income Tax Expense |
$0.00 |
$64,000.00 |
-$21,000.00 |
$241,000.00 |
$34,000.00 |
$45,000.00 |
| Net Income |
-$160.81 M |
-$123.48 M |
-$83.46 M |
-$45.74 M |
-$19.24 M |
-$13.73 M |
| Net Income Ratio |
0 |
0 |
0 |
-38.7 |
-4.01 |
-6.64 |
| EPS |
-3.74 |
-3.03 |
-2.07 |
-1.15 |
-0.53 |
-0.63 |
| EPS Diluted |
-3.74 |
-3.03 |
-2.07 |
-1.15 |
-0.53 |
-0.63 |
| Weighted Average Shares
Out |
$42.99 M
|
$40.70 M
|
$40.31 M
|
$39.84 M
|
$36.49 M
|
$21.95 M
|
| Weighted Average Shares
Out Diluted |
$42.99 M
|
$40.70 M
|
$40.31 M
|
$39.84 M
|
$36.49 M
|
$21.95 M
|
| Link |
|
|
|
|
|
|
